Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

Memphasys Limited (ASX:MEM) Reports September Revenue Growth as Felix Expands Overseas

Australian reproductive biotechnology company Memphasys Limited (ASX:MEM) is expanding international sales activity for its Felix sperm preparation system. Its September 2026 quarterly report, released in October, records higher invoicing, new distribution agreements and further regulatory approvals. Alongside this commercial activity, the company received additional …

Aditi Sarkar | 19 October 2026

Imagion Biosystems Limited (ASX:IBX) Advances HER2 Breast Cancer Imaging Trial Preparations

Imagion Biosystems Limited (ASX:IBX) is a clinical-stage medical imaging company developing MagSense, a nanoparticle-based technology intended to identify cancer-associated molecular targets using magnetic resonance imaging (MRI). Its September 2026 update centres on preparations to begin a US clinical trial in HER2-positive breast cancer, with …

Aditi Sarkar | 19 October 2026

Radiopharm Theranostics Limited (ASX:RAD) Advances RAD101 Regulatory Planning Amid FY26 Loss

Radiopharm Theranostics Limited (ASX:RAD) is an Australian clinical-stage developer of radiopharmaceutical products intended for cancer imaging and treatment. Recent attention has centred on its RAD101 brain metastases imaging program after an October meeting with the US Food and Drug Administration (FDA), while its latest …

Aditi Sarkar | 19 October 2026

Invion Limited (ASX:IVX) Reviews Photosoft Development and FY26 Financial Performance

Invion Limited (ASX:IVX) is an Australian biotechnology company developing photodynamic therapy applications based on its Photosoft platform. Its FY26 report documents research expenditure, limited commercial revenue and continuing losses, while recent disclosures describe financing arrangements and collaborations intended to support clinical development. Shares were …

Aditi Sarkar | 19 October 2026

CONNEQT Health Limited (ASX:CQT) Reports Revenue Growth as Digital Health Expansion Continues

CONNEQT Health Limited (ASX:CQT) develops cardiovascular monitoring devices and related digital services for consumers, healthcare providers and researchers. The company’s FY26 results show increased sales from its arterial health technology, alongside continuing operating losses and a need to manage funding. Its recent US distribution …

Aditi Sarkar | 19 October 2026

ReNerve Limited (ASX:RNV) Reports Nerve Repair Study Data as Commercial Rollout Expands

At the time of writing this article on 19 October 2026, ReNerve shares were trading at AUD 0.084, up 9.09% during today's trading session. This is a market snapshot rather than a measure of clinical or commercial performance.

Aditi Sarkar | 19 October 2026

Identifai Genetics (ASX:ID1): ASX Debut, Prenatal Screening Plans and Interim Results

Identifai focuses on non-invasive prenatal screening using genetic material obtained from a maternal blood sample. Its Windrose platform is being developed to examine genetic conditions through genome-wide sequencing and machine-learning analysis. The company describes a workflow that combines cell-free DNA sequencing with its analytical …

Aditi Sarkar | 19 October 2026

Microba Life Sciences (ASX:MAP): FY26 Testing Growth, Financial Results and GI Navigator Plans

Microba Life Sciences Limited (ASX:MAP), an Australian microbiome diagnostics and therapeutics business, entered FY27 after reshaping its product range around clinical testing and own-brand supplements. At the time of writing this article on 19 October 2026, its shares were quoted at AUD 0.044, up …

Aditi Sarkar | 19 October 2026

Avecho Biotechnology Limited (ASX:AVE): Phase III Insomnia Trial Progress and Commercial Plans

Avecho develops and licenses pharmaceutical delivery technologies built around its proprietary tocopheryl phosphate mixture, known as TPM. Its principal clinical asset is a TPM-enhanced CBD soft-gel formulation under investigation for treating insomnia. The company also identifies applications for its delivery platform in pharmaceutical and …

Aditi Sarkar | 19 October 2026

Syntara Limited (ASX:SNT) Updates Clinical Trials and Research Funding

At the time of writing on 19 October 2026, Syntara shares were trading at AUD 0.020, an increase of 5.26% during the day’s trading session.

Aditi Sarkar | 19 October 2026
Support

Hi! How can we help you today?

Loading…